HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Syrengelas, A. D. Articles by Levy, R. Search for Related Content PubMed PubMed Citation Articles by Syrengelas, A. D. Articles by Levy, R.

DNA Vaccination Against the Idiotype of a Murine B Cell Lymphoma: Mechanism of Tumor Protection¹

Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA 94305

Several studies have shown that immunization with DNA, which encodes the idiotypic determinants of a B cell lymphoma, generates tumor-specific immunity. Although induction of antiidiotypic Abs has correlated with tumor protection, the effector mechanisms that contribute to tumor protection have not been clearly identified. This study evaluated the tumor protective effects of humoral and cellular immune mechanisms recruited by idiotype-directed DNA vaccines in the 38C13 murine B cell lymphoma model. Antiidiotypic Abs induced by DNA vaccination supported in vitro complement-mediated cytotoxicity of tumor cells, and simultaneous transfer of tumor cells and hyperimmune sera protected naive animals against tumor growth. However, in vitro stimulation of immune splenocytes with tumor cells failed to induce idiotype-specific cytotoxicity, and following vaccination, depletion of CD4 or CD8 T cell subsets did not compromise protection. Furthermore, protection of naive recipients against tumor challenge could not be demonstrated either by a Winn assay approach or by adoptive transfer of spleen and lymph node cells. Thus, in this experimental model, current evidence suggests that the tumor-protective effects of DNA vaccination can be largely attributed to idiotype-specific humoral immunity.

This article has been cited by other articles:

				A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study PNAS, July 22, 2008; 105(29): 10131 - 10136. [Abstract] [Full Text] [PDF]

				S. N. Franki, K. K. Steward, D. J. Betting, K. Kafi, R. E. Yamada, and J. M. Timmerman Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo Blood, February 1, 2008; 111(3): 1504 - 1511. [Abstract] [Full Text] [PDF]

				D. G. Maloney Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines J. Clin. Oncol., September 10, 2005; 23(26): 6421 - 6428. [Abstract] [Full Text] [PDF]

				S. Muraro, A. Bondanza, M. Bellone, P. D. Greenberg, and C. Bonini Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses Blood, May 1, 2005; 105(9): 3596 - 3604. [Abstract] [Full Text] [PDF]

				W.-K. Weng, D. Czerwinski, J. Timmerman, F. J. Hsu, and R. Levy Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype J. Clin. Oncol., December 1, 2004; 22(23): 4717 - 4724. [Abstract] [Full Text] [PDF]

				D. Winter, E. Fiebiger, P. Meraner, H. Auer, C. Brna, R. Strohal, F. Trautinger, R. Knobler, G. F. Fischer, G. Stingl, et al. Definition of TCR Epitopes for CTL-Mediated Attack of Cutaneous T Cell Lymphoma J. Immunol., September 1, 2003; 171(5): 2714 - 2724. [Abstract] [Full Text] [PDF]

				K. U. Lundin, P. O. Hofgaard, H. Omholt, L. A. Munthe, A. Corthay, and B. Bogen Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies Blood, July 15, 2003; 102(2): 605 - 612. [Abstract] [Full Text] [PDF]

				H.-W. Chen, Y.-P. Lee, Y.-F. Chung, Y.-C. Shih, J.-P. Tsai, M.-H. Tao, and C.-C. Ting Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy Int. Immunol., March 1, 2003; 15(3): 427 - 435. [Abstract] [Full Text] [PDF]

				E. Gatza and C. Y. Okada Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma J. Immunol., November 1, 2002; 169(9): 5227 - 5235. [Abstract] [Full Text] [PDF]

				A. M. Krackhardt, M. Witzens, S. Harig, F. S. Hodi, A. J. Zauls, M. Chessia, P. Barrett, and J. G. Gribben Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX Blood, August 28, 2002; 100(6): 2123 - 2131. [Abstract] [Full Text] [PDF]

				A. C. Armstrong, S. Dermime, C. G. Allinson, T. Bhattacharyya, K. Mulryan, K. R. Gonzalez, P. L. Stern, and R. E. Hawkins Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope J. Immunol., April 15, 2002; 168(8): 3983 - 3991. [Abstract] [Full Text] [PDF]

				K. Haupt, M. Roggendorf, and K. Mann The Potential of DNA Vaccination against Tumor-Associated Antigens for Antitumor Therapy Experimental Biology and Medicine, April 1, 2002; 227(4): 227 - 237. [Abstract] [Full Text] [PDF]

				J. M. Timmerman, D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood, March 1, 2002; 99(5): 1517 - 1526. [Abstract] [Full Text] [PDF]

				J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas Blood, March 1, 2001; 97(5): 1370 - 1377. [Abstract] [Full Text] [PDF]

				Z. You, J. Hester, L. Rollins, G. C. Spagnoli, P. van der Bruggen, and S.-Y. Chen A Retrogen Strategy for Presentation of an Intracellular Tumor Antigen as an Exogenous Antigen by Dendritic Cells Induces Potent Antitumor T Helper and CTL Responses Cancer Res., January 1, 2001; 61(1): 197 - 205. [Abstract] [Full Text]

				C. P. Wong and R. Levy Recombinant Adenovirus Vaccine Encoding a Chimeric T-Cell Antigen Receptor Induces Protective Immunity against a T-Cell Lymphoma Cancer Res., May 1, 2000; 60(10): 2689 - 2695. [Abstract] [Full Text]

				J. M. Timmerman and R. Levy Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine J. Immunol., May 1, 2000; 164(9): 4797 - 4803. [Abstract] [Full Text] [PDF]

				F. Osterroth, A. Garbe, P. Fisch, and H. Veelken Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells Blood, February 15, 2000; 95(4): 1342 - 1349. [Abstract] [Full Text] [PDF]